Neuro-Hitech, Inc. is an early stage pharmaceutical company engaged in the acquisition and development of therapies for Alzheimer's disease and other degenerative neurological disorders. The Company is focused particularly on technologies that address large unmet medical needs and have the potential to enter clinical development within 12 to 24 months after acquisition, and on driving development in a rapid, cost-effective manner.

The Company's most advanced product candidate, Huperzine A, is in Phase II clinical trials in the U.S. and is being tested for efficacy and safety in the treatment of mild to moderate Alzheimer's disease. Huperzine A is a cholinesterase inhibitor that the Company believes may be effective in the treatment of Alzheimer's disease and Mild Cognitive Impairment ("MCI"), although, to date, its efforts have been focused upon Huperzine A's effectiveness in Alzheimer's disease. Through a collaboration with the Alzheimer's Disease Cooperative Study ("ADCS"), the Company has completed two Phase I studies. ADCS was formed in 1991 as a cooperative agreement between the National Institute of Aging and the University of California San Diego, with the goal of advancing the research of drugs for treating patients with Alzheimer's disease, the National Institutes of Health ("NIH") and Georgetown University Medical Center ("Georgetown").